CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,580 enrolled
Drug / intervention
methoxy polyethylene glycol-ep [Mircera]drug
Likely dose
Mircera as prescribed by physicianAI-extracted
Key inclusion· 3
  • ✓Age 18 years or older
  • ✓Chronic kidney disease
  • ✓Willing to provide informed consent for data transmission
Key exclusion· 4
  • ✕Serious hematological or infectious disease
  • ✕Acute bleeding within 16 weeks before data collection
  • ✕Currently enrolled in an interventional trial
  • ✕Pregnant or breast-feeding (female patients)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01051323
NCT01051323N/ACompleted
CompareCT.gov

Non-interventional Study to Investigate Hemoglobin Levels and Dose Over Time in the Daily Use of Mircera for Renal Anemia in Larger Centers, and to Detect Differences Between Standard of Care in the Centers

Hoffmann-La Roche·observational·Posted Jan 18, 2010·Updated Dec 18, 2015

In Brief

An observational study evaluating methoxy polyethylene glycol-ep [Mircera] for Anemia. Completed, enrolled 1,580 participants across 1 site.

Detailed Summary

This observational study will investigate hemoglobin levels and Mircera (methoxy polyethyleneglycol-epoetin beta) dose over time in patients with chronic kidney disease, and compare standards of care between centers. Data from each patient will be collected over 12 months of Mircera therapy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 18, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.5 years ago

Interventions

methoxy polyethylene glycol-ep [Mircera]drug

As prescribed by physician